Managed Entry Agreements Could Bring Affordability to Multibillion-Dollar Novel Gene Therapy Market

Cogentia’s Senior Analyst Mark Orchard discusses how managed entry agreements (MEAs) could become a major trend in improving access to affordable gene therapies. He notes that the same drug could be subject to different types of MEAs, such as a pay-for-performance risk share or annuity-based payments. In addition to affordability concerns, payers and pharma should consider the sustainability of their newly developed therapies.

Mark Orchard remarks, “MEAs aim to make the high cost of these one-off treatments more palatable for healthcare payers, who might balk if faced with the entire cost upfront,” adding, “Most importantly, they ensure any uncertainty regarding long-term effects can be addressed while facilitating timely care for patients who are often in desperate need of an effective treatment.” Read more here.

(Source: Mark Orchard, Pharmaceutical Executive, 8/2021)